Qiagen NYSE:QGEN Stock Report

Qiagen N.V. Appoints Eva Pisa as New Supervisory Board Member

Qiagen N.V. at its AGM appointed Dr. Eva Pisa as new Supervisory Board member. Dr. Pisa, brings proven leadership insights and extensive industry experience to QIAGEN that will deeply enrich the capabilities in board in terms of science and business acumen. She most recently served at Roche Diagnostics International from 2007 to 2020, where she held various leadership positions of increasing responsibility. During her tenure, the cobas 6,800 and 8,800 systems were developed and launched. Dr. Pisa, was also responsible for clinical chemistry, endocrinology and the custom biotech business at Roche as well. Before joining Roche, Dr. Pisa, was the CEO of Sangtec Molecular Diagnostics AB, a Swedish molecular diagnostic start-up. Dr. Pisa, holds a PhD from the Karolinska Institute in Sweden and an MBA from Heriot-Watt University in Scotland.

CFO, MD & Member of Management Board recently sold US$1.5m worth of stock

On the 8th of June, Roland Sackers sold around 32k shares on-market at roughly US$47.00 per share. This was the largest sale by an insider in the last 3 months. Roland has been a seller over the last 12 months, reducing personal holdings by US$1.4m.

QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels

QIAGEN N.V. announced the launch ofQIAstat-Dx Rise – a high-capacity version of the QIAstat-Dx automated syndromic system – and enhancements to the menu of tests for the fully integrated one-step molecular testing solution that provides results in about one hour. The launch of QIAstat-Dx Rise comes after the award of European CE-marking that significantly expands QIAGEN’s offering in syndromic testing, which is becoming an increasingly important tool in laboratories settings to test simultaneously for multiple pathogens from one sample. QIAstat-Dx Rise and its test cartridges are a closed system for hands-off sample preparation and processing. With a random access capacity of up to 18 different tests, it can provide diagnostic results for up to 56 tests in an eight-hour shift and 160 tests per day by using eight analytical modules. Building on the existing QIAstat-Dx Analyzer with up to four analytical modules, QIAstat-Dx Rise is a flexible new option for increased testing capacity. The CE-marked QIAstat-Dx Respiratory SARS-CoV-2 Panel has been expanded to test for an additional target, Chlamydophila pneumoniae, a bacteria that is cause of respiratory infections that can present with influenza-like symptoms. This panel can now be used to detect and differentiate among 23 viral and bacterial targets that cause respiratory infections. While C. pneumoniae typically causes mild illness, it can cause severe outcomes in high-risk populations, particularly older adults. The CE-marked QIAstat-Dx Gastrointestinal Panel 2 has also been updated with new features for improved sample preparation and panel performance. This panel can be used to detect and differentiate among 22 viral, bacterial and parasitic targets that cause gastrointestinal infections. Importantly, the panel’s STEC target (Shiga-like toxin E.coli) reports the toxin content (stx1 and stx2). This information can be used to determine the risk of certain patient populations to Hemolytic Uremic Syndrome (HUS) and therefore can help provide the right patient monitoring. QIAGEN also released a software upgrade for QIAstat-Dx Analyzer that enhances the system’s cybersecurity, usability and connectivity features. The release of software version 1.5.1 enables users to configure their devices to perform mandatory External Quality Control tests. The new software adds to the QIAsphere cloud-based connectivity solution that enhances QIAstat-Dx capabilities in digital diagnostics.

Qiagen N.V., Annual General Meeting, Jun 23, 2022